India Labelling under Rule 44 and Sticker Labelling
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Indian labelling requirements for medical devices are set out in Chapter VI (Rules 44 to 48) of the Medical Devices Rules, 2017. The particulars must be printed in indelible ink on the label, or on the shelf pack of the device, or on the outer packaging and every outer layer of packaging. For imported devices, Rule 44(n) allows the importer to add, by stickering, the import licence number, the name and address of the importer, the address of the actual manufacturing site, and the date of manufacture, where those details are not already printed.
- Chapter VI governs labelling for devices generally, and it applies to exempt Class A products as well.
- Stickering is a genuine concession for importers and removes the need for India-specific printing at the factory.
- Only details that are not already printed may be added by sticker; the base label still has to be complete.
- Expiry must be expressed as month and year, preceded by the words Expiry date or Shelf Life.
- Chapter VI is not among the chapters exempted for Class A devices, so labelling compliance survives the exemption.
2. Legal basis
The labelling obligations sit in Chapter VI and are elaborated in the CDSCO’s published FAQ answers. The table below sets out the specific matters, their sources, and what each requires.
| Where particulars are printed | MDR 2017 Rule 44; CDSCO FAQ question 46 | The particulars must be printed in indelible ink on the label, the shelf pack, the outer packaging, and every outer layer of packaging |
| Sticker labelling | MDR 2017 Rule 44(n); CDSCO FAQ question 44 | For imported devices, the importer may complete the following by stickering: import licence number, importer name and address, actual manufacturing site address, and date of manufacture |
| Expiry marking | MDR 2017 Rule 44(e); CDSCO FAQ question 45 | Expiry must be stated in month and year, meaning the device may be used until the last day of that month, and must be preceded by the words “Expiry date” or “Shelf Life” |
| Scope of Chapter VI | MDR 2017 Chapter VI | Applies to all devices, including Class A products under exempt registration (CDSCO FAQ question 69) |
3. Expert insights
Insight one: stickering is a significant convenience granted to importers. It means the overseas manufacturer does not need to print market-specific packaging carrying the Indian licence number. The import licence number, the importer information, and the date of manufacture can be applied by the importer after the goods arrive at port. For exporters with small batches and wide product ranges, this is a material cost saving, because a single factory label design can serve the Indian market alongside others without a separate print run.
Insight two: what is stickered is “details not already printed”, not the entire label. The wording of Rule 44(n) is “when such details are not already printed” — it applies only to the missing portions. Baseline elements such as the product name, the manufacturer, the batch number, and the expiry date must still be printed on the original label. Importers who treat the sticker as a complete label replacement are misreading the provision, and the error usually surfaces at customs or during a post-market inspection.
Insight three: Chapter VI still applies to exempt products. Although Class A products that are neither sterile nor measuring are exempt from the manufacturing and import licensing chapters, the labelling chapter, Chapter VI, is not on the exemption list — the CDSCO FAQ question 69 identifies chapters IV, V, VII, VIII, and XI as the exempted ones. Products taking the exemption route must still get their labelling right. The exemption reduces the licensing burden; it does not reduce the labelling obligation.
Insight four: the expiry format is mandatory. Only the month and the year are written, and the words “Expiry date” or “Shelf Life” must precede them. Writing DD/MM/YY is non-compliant. The requirement looks trivial, yet it is a fixed, checkable formatting rule, and it is one of the few labelling points that a reviewer can verify at a glance without any technical context.
4. Practical recommendations
GRZAN structures the labelling solution for clients in two layers. The factory layer carries the product name, the manufacturer name and address, the net content, the batch or serial number, the month and year of manufacture, the month and year of expiry, storage conditions, warnings and precautions, and the intended use. The sticker layer carries the import licence number, the importer name and address, the actual manufacturing site address, and the date of manufacture. We produce the sticker artwork as a print-ready file matched to actual practice at Indian ports of entry, and we specify the sticker position, so that the goods are not treated as repackaged during clearance.
- Separate the label artwork into a factory layer and a sticker layer from the outset.
- Confirm that every baseline element remains printed on the original label before adding a sticker.
- Match the sticker artwork to port practice and specify placement to avoid repackaging findings.
- Check that wording for exempt Class A products still satisfies Chapter VI.
- Verify the expiry field format against Rule 44(e) before the artwork is released.
5. Verification checklist
- □ The factory label already contains the product name, manufacturer, batch number, and expiry date
- □ The expiry is in month plus year format and is preceded by Expiry date or Shelf Life
- □ The sticker artwork contains the import licence number, importer name and address, actual manufacturing site address, and date of manufacture
- □ The label is printed in indelible ink on the label, shelf pack, and outer packaging
- □ Exempt Class A products have been confirmed as still subject to the Chapter VI labelling requirements
Regulatory information verified as of 27 October 2026.
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including India. Our team prepares dossiers to CDSCO expectations, manages SUGAM submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us